Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma

Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More